About | Free Trial

Last Update

2016-04-14T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Peter Mueller?

Dr. Peter Mueller R.

President of Research and Development and CSO

Pronutria Inc

Direct Phone: (617) ***-**** ext. ***       

Email: p***@***.com

Pronutria Inc

840 Memorial Drive Third Floor

Cambridge, Massachusetts 02139

United States

Company Description

Pronutria created a revolutionary platform for identifying protein nutrients from within the human diet that have potent pharmacological effects, opening a vast untapped source of safe, breakthrough medicines. Pharmaconutrients, are a class of pharmacolog ... more

Find other employees at this company (63)

Background Information

Employment History

President
Epicenter Consulting LLC

Affiliations

Advisory Board Member
USA India Chamber of commerce

Advisory Board Member
Phacilitate Limited

CSO and Executive Vice President Global Research and Development
Vertex Pharmaceuticals Incorporated

Education

MBA

Babson

Ph.D.
Pharmacology
University of Mainz

Ph.D. degree
pharmaceuticals
University of Mainz , Germany

PhD
Chemistry
Albert Einstein University of Ulm , Germany

undergraduate degree

Albert Einstein University of Ulm , Germany

Web References (195 Total References)


Volume Buzz: Keryx Biopharmaceuticals (NASDAQ:KERX), Arrowhead Research Corp (NASDAQ:ARWR), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) | US Market Buzz

www.usmarketbuzz.com [cached]

The company on July 10 announced that Peter Mueller, Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company. Dr. Mueller's retirement will be effective October 31, 2014, following a planned transition period. Dr. Mueller joined Vertex in 2003 as Chief Scientific Officer and Senior Vice President, Drug Discovery and Innovation.


Board of Directors | Inhibikase Therapeutics, Inc.

www.inhibikase.com [cached]

Peter Mueller, PhD.

Dr. Mueller joined Vertex in July 2003. As Executive Vice President Global Research and Development & Chief Scientific Officer, he provides strategic oversight for Vertex's worldwide drug discovery research programs, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations as well as Clinical and Non-Clinical Development, Regulatory, Patient Safety and Medical Affairs. Key areas of Vertex' R&D are Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases which led in 2011 to the successful approval and launch of INCIVEK (HepC), a NDA/MAA submission for KALYDECO (CF) with the first approval in the US in January 2012 and several proof of clinical concept candidates in various disease areas. Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for the development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.


Peter Mueller, Ph.D., President of R&D and Chief Scientific Officer , Pronutria BioSciences LLC

usaindiachamber.org [cached]

Peter Mueller, Ph.D. President of R&D and Chief Scientific Officer Pronutria BioSciences LLC

In November 2014, Dr. Mueller joined Pronutria Biosciences LLC as the President of Research and Development & Chief Scientific Officer. Prior to his time at Pronutria, Dr. Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals, starting there in 2003. At Vertex, he provided strategic oversight for Vertex's worldwide drug discovery and development programs. He was responsible to build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain, Clinical and Non-Clinical Development, Regulatory and Medical Affairs as well as Patient Safety. Key areas of Vertex' R&D have been Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases. His leadership led in 2011 to the successful approval and launch of INCIVEK (HepC), and a NDA, MAA and numerous sNDA submission(s) for KALYDECO (CF) with the first approval in the US on January 31, 2012 followed by consecutive approvals in the EU, Canada and Australia. Both Breakthrough Therapies got awarded the prestigious Prix Galien award (US, Telaprevir) or its European counterpart the Galenus Preis (Kalydeco). The combination therapy lumacaftor/ivacaftor intended to treat the majority of Cystic fibrosis patients carrying the 508del mutation finished phase 3 successfully and entered into registration. In addition, several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA) enhanced Vertex's drug pipeline as well as numerous preclinical candidates (MS, IBD, Cancer, TB). Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for Research in North America and the Development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He played a key role in the development of Spiriva, Combivent and Atrovent. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, starting there in 1984, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.


Peter Mueller, Ph.D., President of R&D and Chief Scientific Officer , Pronutria BioSciences LLC

www.usaindiachamber.org [cached]

Peter Mueller, Ph.D. President of R&D and Chief Scientific Officer Pronutria BioSciences LLC

In November 2014, Dr. Mueller joined Pronutria Biosciences LLC as the President of Research and Development & Chief Scientific Officer. Prior to his time at Pronutria, Dr. Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals, starting there in 2003. At Vertex, he provided strategic oversight for Vertex's worldwide drug discovery and development programs. He was responsible to build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain, Clinical and Non-Clinical Development, Regulatory and Medical Affairs as well as Patient Safety. Key areas of Vertex' R&D have been Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases. His leadership led in 2011 to the successful approval and launch of INCIVEK (HepC), and a NDA, MAA and numerous sNDA submission(s) for KALYDECO (CF) with the first approval in the US on January 31, 2012 followed by consecutive approvals in the EU, Canada and Australia. Both Breakthrough Therapies got awarded the prestigious Prix Galien award (US, Telaprevir) or its European counterpart the Galenus Preis (Kalydeco). The combination therapy lumacaftor/ivacaftor intended to treat the majority of Cystic fibrosis patients carrying the 508del mutation finished phase 3 successfully and entered into registration. In addition, several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA) enhanced Vertex's drug pipeline as well as numerous preclinical candidates (MS, IBD, Cancer, TB). Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for Research in North America and the Development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He played a key role in the development of Spiriva, Combivent and Atrovent. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, starting there in 1984, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.


Inhibikase Therapeutics Elects Peter Mueller, Ph.D., to Board of Directors – Manufacturing Digital (press release) | Logo Informer

www.logoinformer.com [cached]

Inhibikase Therapeutics Elects Peter Mueller, Ph.D., to Board of Directors – Manufacturing Digital (press release) Inhibikase Therapeutics Elects Peter Mueller, Ph.D., to Board of Directors - Manufacturing Digital (press release) | Logo Informer

...
Inhibikase Therapeutics Elects Peter Mueller, Ph.D., to Board of Directors - Manufacturing Digital (press release) graphic designer by CHERLEENLIU
ATLANTA, March 9, 2012 /PRNewswire/ - Inhibikase Therapeutics, Inc. today announced the election of Dr. Peter Mueller of Vertex Pharmaceuticals to the Board of Directors of Inhibikase Therapeutics, Inc. (LOGO: ...

Similar Profiles

Other People with this Name

Other people with the name Mueller

Kurt Mueller
Grainger plc

Gregory Mueller
Aesthetic Show

Joel Mueller

Michelle Mueller
Regional Office of Education

Rick Mueller
Rick Mueller

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory